All Family Resources
All Clinician Resources

Update on a Promising New Drug to Treat JM: Vamorolone

Cure JM is making extraordinary progress in juvenile myositis (JM) research, including a partnership with ReveraGen Biotech to advance the drug vamorolone toward a clinical trial in JM.

Vamorolone is a steroid replacement with all the benefits of steroid treatment without devastating side effects. Vamorolone is currently in a clinical trial in Duchenne Muscular Dystrophy children.

Findings so far indicate improved safety relative to prednisone. Cure JM is working with vamorolone’s sponsor, ReveraGen, to design a clinical trial to test the drug’s safety in JM children. ReveraGen’s VP of Research, Eric Hoffmann, Ph.D., gives us an update on vamorolone and the status of a clinical trial in JM.

Jim’s 2024 Resolutions

Each January, I share with our community a few personal New Year’s resolutions for the year ahead. I believe these resolutions help us keep a keen focus on the priorities that matter most—better treatments, better care, and a cure for JM.

Resilient Parenting

Parenting a child with a rare disease comes with unique challenges—but you don’t have to navigate them alone. Join us for a powerful and practical

Exercise and Juvenile Myositis

In this presentation, Dr. Laura Tasan explains the importance of exercise for JM patients. Since JM children suffer from endurance and fatigue issues, exercise for

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Join Now
Cure JM supports families, patients, and the juvenile myositis research community.

Interested in DIY fundraising but need help?

We’re here to help!

To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.